Editing Designer drug (section)

====1960s–1970s====
During the 1960s and 1970s, a number of new synthetic hallucinogens were introduced, with a notable example being the sale of highly potent tablets of [[2,5-Dimethoxy-4-methylamphetamine|DOM]] in [[San Francisco]] in 1967.<ref>{{cite journal |vauthors=Snyder SH, Faillace L, Hollister L |title=2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug |journal=Science |volume=158 |issue=3801 |pages=669–70 |year=1967 |pmid=4860952 |doi=10.1126/science.158.3801.669 |bibcode=1967Sci...158..669S |s2cid=24065654 }}</ref> There was little scope to prosecute people over drug analogues at this time, with new compounds instead being added to the controlled drug schedules one by one as they became a problem. One significant court case from this period was in 1973, when [[Tim Scully]] and [[Nicholas Sand]] were prosecuted for making the acetyl amide of [[Lysergic acid diethylamide|LSD]], known as [[ALD-52]].{{Citation needed|date=December 2019}} At this time ALD-52 was not a controlled drug, but they were convicted on the grounds that in order to make ALD-52, they would have had to be in possession of LSD, which was illegal. The late 1960s also saw the introduction of various analogues of [[phencyclidine]] (PCP) to the illicit market, with [[Eticyclidine]] (PCE) first being detected in 1969.<ref>{{Cite journal |last1=Morris |first1=Hamilton |last2=Wallach |first2=Jason |date=July 2014 |title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs |url=https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1620 |journal=Drug Testing and Analysis |language=en |volume=6 |issue=7–8 |pages=614–632 |doi=10.1002/dta.1620 |pmid=24678061 |issn=1942-7603|url-access=subscription }}</ref>